383 related articles for article (PubMed ID: 25512383)
1. Mechanistic analysis of the role of bromodomain-containing protein 4 (BRD4) in BRD4-NUT oncoprotein-induced transcriptional activation.
Wang R; You J
J Biol Chem; 2015 Jan; 290(5):2744-58. PubMed ID: 25512383
[TBL] [Abstract][Full Text] [Related]
2. Ectopic protein interactions within BRD4-chromatin complexes drive oncogenic megadomain formation in NUT midline carcinoma.
Alekseyenko AA; Walsh EM; Zee BM; Pakozdi T; Hsi P; Lemieux ME; Dal Cin P; Ince TA; Kharchenko PV; Kuroda MI; French CA
Proc Natl Acad Sci U S A; 2017 May; 114(21):E4184-E4192. PubMed ID: 28484033
[TBL] [Abstract][Full Text] [Related]
3. Combined Targeting of the BRD4-NUT-p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734.
Morrison-Smith CD; Knox TM; Filic I; Soroko KM; Eschle BK; Wilkens MK; Gokhale PC; Giles F; Griffin A; Brown B; Shapiro GI; Zucconi BE; Cole PA; Lemieux ME; French CA
Mol Cancer Ther; 2020 Jul; 19(7):1406-1414. PubMed ID: 32371576
[TBL] [Abstract][Full Text] [Related]
4. Perturbation of BRD4 protein function by BRD4-NUT protein abrogates cellular differentiation in NUT midline carcinoma.
Yan J; Diaz J; Jiao J; Wang R; You J
J Biol Chem; 2011 Aug; 286(31):27663-75. PubMed ID: 21652721
[TBL] [Abstract][Full Text] [Related]
5. Activation of SOX2 expression by BRD4-NUT oncogenic fusion drives neoplastic transformation in NUT midline carcinoma.
Wang R; Liu W; Helfer CM; Bradner JE; Hornick JL; Janicki SM; French CA; You J
Cancer Res; 2014 Jun; 74(12):3332-43. PubMed ID: 24736545
[TBL] [Abstract][Full Text] [Related]
6. Oncogenesis by sequestration of CBP/p300 in transcriptionally inactive hyperacetylated chromatin domains.
Reynoird N; Schwartz BE; Delvecchio M; Sadoul K; Meyers D; Mukherjee C; Caron C; Kimura H; Rousseaux S; Cole PA; Panne D; French CA; Khochbin S
EMBO J; 2010 Sep; 29(17):2943-52. PubMed ID: 20676058
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic targeting of p300/CBP HAT domain for the treatment of NUT midline carcinoma.
Zhang X; Zegar T; Lucas A; Morrison-Smith C; Knox T; French CA; Knapp S; Müller S; Siveke JT
Oncogene; 2020 Jun; 39(24):4770-4779. PubMed ID: 32366905
[TBL] [Abstract][Full Text] [Related]
8. Structural mechanism of BRD4-NUT and p300 bipartite interaction in propagating aberrant gene transcription in chromatin in NUT carcinoma.
Yu D; Liang Y; Kim C; Jaganathan A; Ji D; Han X; Yang X; Jia Y; Gu R; Wang C; Zhang Q; Cheung KL; Zhou MM; Zeng L
Nat Commun; 2023 Jan; 14(1):378. PubMed ID: 36690674
[TBL] [Abstract][Full Text] [Related]
9. Supercharging BRD4 with NUT in carcinoma.
Eagen KP; French CA
Oncogene; 2021 Feb; 40(8):1396-1408. PubMed ID: 33452461
[TBL] [Abstract][Full Text] [Related]
10. Chemical Screen Identifies Diverse and Novel Histone Deacetylase Inhibitors as Repressors of NUT Function: Implications for NUT Carcinoma Pathogenesis and Treatment.
Shiota H; Alekseyenko AA; Wang ZA; Filic I; Knox TM; Luong NM; Huang Y; Scott DA; Jones KL; Gokhale PC; Lemieux ME; Cole PA; Kuroda MI; French CA
Mol Cancer Res; 2021 Nov; 19(11):1818-1830. PubMed ID: 34285087
[TBL] [Abstract][Full Text] [Related]
11. Novel BRD4-NUT fusion isoforms increase the pathogenic complexity in NUT midline carcinoma.
Thompson-Wicking K; Francis RW; Stirnweiss A; Ferrari E; Welch MD; Baker E; Murch AR; Gout AM; Carter KW; Charles AK; Phillips MB; Kees UR; Beesley AH
Oncogene; 2013 Sep; 32(39):4664-74. PubMed ID: 23128391
[TBL] [Abstract][Full Text] [Related]
12. BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells.
French CA; Ramirez CL; Kolmakova J; Hickman TT; Cameron MJ; Thyne ME; Kutok JL; Toretsky JA; Tadavarthy AK; Kees UR; Fletcher JA; Aster JC
Oncogene; 2008 Apr; 27(15):2237-42. PubMed ID: 17934517
[TBL] [Abstract][Full Text] [Related]
13. The oncogenic BRD4-NUT chromatin regulator drives aberrant transcription within large topological domains.
Alekseyenko AA; Walsh EM; Wang X; Grayson AR; Hsi PT; Kharchenko PV; Kuroda MI; French CA
Genes Dev; 2015 Jul; 29(14):1507-23. PubMed ID: 26220994
[TBL] [Abstract][Full Text] [Related]
14. Molecular features driving condensate formation and gene expression by the BRD4-NUT fusion oncoprotein are overlapping but distinct.
Kosno M; Currie SL; Kumar A; Xing C; Rosen MK
Sci Rep; 2023 Jul; 13(1):11907. PubMed ID: 37488172
[TBL] [Abstract][Full Text] [Related]
15. NSD3-NUT fusion oncoprotein in NUT midline carcinoma: implications for a novel oncogenic mechanism.
French CA; Rahman S; Walsh EM; Kühnle S; Grayson AR; Lemieux ME; Grunfeld N; Rubin BP; Antonescu CR; Zhang S; Venkatramani R; Dal Cin P; Howley PM
Cancer Discov; 2014 Aug; 4(8):928-41. PubMed ID: 24875858
[TBL] [Abstract][Full Text] [Related]
16. Bromodomain Protein BRD4 Is a Transcriptional Repressor of Autophagy and Lysosomal Function.
Sakamaki JI; Wilkinson S; Hahn M; Tasdemir N; O'Prey J; Clark W; Hedley A; Nixon C; Long JS; New M; Van Acker T; Tooze SA; Lowe SW; Dikic I; Ryan KM
Mol Cell; 2017 May; 66(4):517-532.e9. PubMed ID: 28525743
[TBL] [Abstract][Full Text] [Related]
17. Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628.
Stathis A; Zucca E; Bekradda M; Gomez-Roca C; Delord JP; de La Motte Rouge T; Uro-Coste E; de Braud F; Pelosi G; French CA
Cancer Discov; 2016 May; 6(5):492-500. PubMed ID: 26976114
[TBL] [Abstract][Full Text] [Related]
18. miR-766-5p Targets Super-Enhancers by Downregulating CBP and BRD4.
Gen Y; Muramatsu T; Inoue J; Inazawa J
Cancer Res; 2021 Oct; 81(20):5190-5201. PubMed ID: 34353856
[TBL] [Abstract][Full Text] [Related]
19. Small-Molecule Targeting of BET Proteins in Cancer.
French CA
Adv Cancer Res; 2016; 131():21-58. PubMed ID: 27451123
[TBL] [Abstract][Full Text] [Related]
20. MYC, a downstream target of BRD-NUT, is necessary and sufficient for the blockade of differentiation in NUT midline carcinoma.
Grayson AR; Walsh EM; Cameron MJ; Godec J; Ashworth T; Ambrose JM; Aserlind AB; Wang H; Evan G; Kluk MJ; Bradner JE; Aster JC; French CA
Oncogene; 2014 Mar; 33(13):1736-1742. PubMed ID: 23604113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
